Selinexor Combination Ph 1 Study

December 14, 2021 updated by: Martin Gutierrez

An Investigator Sponsored Phase I/II Study of Selinexor in Combination With Irinotecan in Adults With Solid Tumors

The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New Jersey
      • Hackensack, New Jersey, United States, 07601
        • John Theurer Cancer Center at HackensackUMC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Must have histologically confirmed solid tumor malignancy that is metastatic or unresectable for which standard curative measures do not exist, or are associated with minimal patient survival benefit, and for whom irinotecan therapy may be appropriate.
  • Any prior therapy must have been completed > 2 weeks prior to enrollment on the protocol in patients participating and must have recovered to eligibility levels (CTCAE grade </= 1) from prior toxicity. Prior radiation or surgery should have been completed > 2 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels.
  • Age >/= 18 years. Because no dosing or adverse event (AE) data are currently available on the use of selinexor in patients < 18 years of age, children are excluded from this study, but may be eligible for future pediatric Phase 1 combination trials.
  • Eastern Cooperative Group (ECOG) performance status </= 2 (Karnofsky >/= 60%).
  • Life expectancy >/= 3 months.
  • Patients must have normal organ and marrow function as defined below:
  • Absolute Neutrophil count >/= 1,500u/L
  • Platelets >/= 125,000u/L
  • Total Bilirubin </= 1.5x institution upper limit of normal
  • AST (SGOT)/ALT(SGPT) </= 2.5x institutional upper limit of normal, if liver metastasis </= 5x institutional upper limit.
  • Creatinine </= 1.5x institutional upper limit of normal. or
  • Creatinine clearance >/= 50mL/minute for patients with creatininelevels > 1.5x institutional upper limit of normal.
  • The effects of selinexor on the developing human fetus are unknown. For this reason, and because Irinotecan used in this trial are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 30 days after completion of study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Patients who have previously

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study, or those who have not recovered from AEs due to agents administered more than 2 weeks earlier. Patients must be >/= 2 weeks since any investigational agent was administered as part of an exploratory IND study and should have recovered to eligibility levels from any toxicity.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrythmia, prolonged QTc interval (>500 msec), or psychiatric illness/social situations that would limit compliance with study requirements.
  • In the Food and Drug Administration (FDA) Use-in-Pregnancy Ratings for Drugs, Irinotecan is classified as category D drugs, indicating that investigational or postmarketing data show risk to the fetus. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days after completion of study. Should a woman become pregnant or suspect she is pregnant while participating in the study, she should inform her treating physician immediately. Because there is a risk for AEs in nursing infants secondary to treatment of the mother with these drugs, breastfeeding should be discontinued while the patient is on this trial and for 30 days after completion of treatment on this trial.
  • Patients with known brain metastases are excluded from this clinical trial, with the exception of patients whose brain metastatic disease status is stable with or without treatment without steroids (except for maintenance replacement doses of steroids).
  • Patients with clinically significant illnesses which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies or confirmed diagnosis of HIV infection, Hepatitis B, Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements are excluded from this trial.
  • Grade >/= 3 toxicity related to irinotecan for patients who have received prior irinotecan.
  • Both men and women of all races and ethnic groups are eligible for this trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dose Level -1
Selinexor 12mg po twice weekly (Monday & Wednesday or Tuesday & Thursday); Irinotecan 50mg/m2 IV once daily on days 1, 8 & 15
Drug: Irinotecan
Other Names:
  • Camptosar
Drug: Selinexor
Other Names:
  • KPT-330
Experimental: Dose Level 1
Selinexor 15mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 & 15.
Drug: Irinotecan
Other Names:
  • Camptosar
Drug: Selinexor
Other Names:
  • KPT-330
Experimental: Dose Level 2
Selinexor 20mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 100mg/m2 IV once daily on days 1, 8 & 15.
Drug: Irinotecan
Other Names:
  • Camptosar
Drug: Selinexor
Other Names:
  • KPT-330
Experimental: Dose Level 3
Selinexor 30mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 & 15.
Drug: Irinotecan
Other Names:
  • Camptosar
Drug: Selinexor
Other Names:
  • KPT-330
Experimental: Dose Level 4
Selinexor 30mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 125mg/m2 IV once daily on days 1, 8 & 15.
Drug: Irinotecan
Other Names:
  • Camptosar
Drug: Selinexor
Other Names:
  • KPT-330

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03
Time Frame: From date of first dose through study completion, an average of 1 year
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03
From date of first dose through study completion, an average of 1 year
Establish the maximum tolerated dose (MTD) for the combination of selinexor with Irinotecan.
Time Frame: From date of first dose through study completion, an average of 1 year
Establish the maximum tolerated dose (MTD) for the combination of selinexor with Irinotecan.
From date of first dose through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Martin Gutierrez

Collaborators

Hackensack Meridian Health
Karyopharm Therapeutics Inc

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2014

Primary Completion (Anticipated)

September 1, 2015

Study Completion (Anticipated)

September 1, 2015

Study Registration Dates

First Submitted

June 17, 2019

First Submitted That Met QC Criteria

December 14, 2021

First Posted (Actual)

January 4, 2022

Study Record Updates

Last Update Posted (Actual)

January 4, 2022

Last Update Submitted That Met QC Criteria

December 14, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IST: PRO5126

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Solid Tumor Malignancy

Clinical Trials on Irinotecan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe